TimesSquare Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

TimesSquare Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-203,737	Closed	-$8.96M	–	162
2024 Q2	$8.96M	Sell	203,737 -5,750	-3%	-$244K	0.14%	140
2024 Q1	$10.5M	Sell	209,487 -279,318	-57%	-$15.2M	0.15%	142
2023 Q4	$29.5M	Buy	488,805 +77,590	+19%	+$4M	0.43%	93
2023 Q3	$23.4M	Buy	411,215 +381,215	+1,271%	+$21M	0.36%	109
2023 Q2	$1.53M	Buy	+30,000	New	+$807K	0.02%	165

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

TimesSquare Capital Management's MLTX Position: Q3 2024 in Review

TimesSquare Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2024, closing a stake of 203,737 shares — an estimated $8.96M sold.

TimesSquare Capital Management first reported a position in MLTX in Q2 2023 and held it in 5 quarters. The position peaked at $29.5M in Q4 2023. 109 funds tracked by Wall St. Rank hold MLTX as of Q3 2024.

TimesSquare Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
TimesSquare Capital Management sold 203,737 MoonLake Immunotherapeutics shares in Q3 2024, an estimated $8.96M.
TimesSquare Capital Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 5 quarters.
TimesSquare Capital Management's MoonLake Immunotherapeutics position peaked at $29.5M in Q4 2023.
109 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2024.

Based on TimesSquare Capital Management's 13F filing for Q3 2024, filed 4 Nov 2024.